{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:10:10Z","timestamp":1784999410216,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Commonwealth Department of Health"},{"DOI":"10.13039\/501100001202","name":"Gastroenterological Society of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s10620-022-07483-y","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T13:09:52Z","timestamp":1652447392000},"page":"291-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1821-4969","authenticated-orcid":false,"given":"Paul J.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-3006","authenticated-orcid":false,"given":"Patricia C.","family":"Valery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"Zekry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Bollipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"McGarity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry","family":"Macquillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Nicoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart K.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"7483_CR1","volume-title":"The economic cost and health burden of liver diseases in Australia","author":"Deloitte Access Economics","year":"2013","unstructured":"Deloitte Access Economics. The economic cost and health burden of liver diseases in Australia. Sydney: Gastroenterological Society of Australia\/Australian Liver Association; 2013."},{"issue":"Suppl 1","key":"7483_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"21","author":"H Razavi","year":"2014","unstructured":"Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W et al. The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm. J Viral Hepat 2014;21:34\u201359.","journal-title":"J Viral Hepat"},{"key":"7483_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jhep.2019.04.014","volume":"71","author":"M Alavi","year":"2019","unstructured":"Alavi M, Law MG, Valerio H, Grebely J, Amin J, Hajarizadeh B, Selvey C et al. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales. Australia. J Hepatol 2019;71:281\u2013288.","journal-title":"Australia. J Hepatol"},{"key":"7483_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S2055-6640(20)30270-3","volume":"4","author":"A Lee","year":"2018","unstructured":"Lee A, Hanson J, Fox P, Spice G, Russell D, Boyd P. A decentralised, multidisciplinary model of care facilitates treatment of hepatitis C in regional Australia. J Virus Erad 2018;4:160\u2013164.","journal-title":"J Virus Erad"},{"key":"7483_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/jvh.12870","volume":"25","author":"S Gupta","year":"2018","unstructured":"Gupta S, Rout G, Patel AH, Mahanta M, Kalra N, Sahu P, Sethia R et al. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection. J Viral Hepat 2018;25:771\u2013778.","journal-title":"J Viral Hepat"},{"key":"7483_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","volume":"47","author":"BL Norton","year":"2017","unstructured":"Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, Cunningham CO, Johnson N et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 2017;47:196\u2013201.","journal-title":"Int J Drug Policy"},{"key":"7483_CR7","doi-asserted-by":"crossref","unstructured":"Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, et al. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study. Hepatol Commun 2021.","DOI":"10.1002\/hep4.1826"},{"key":"7483_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/liv.14849","volume":"41","author":"CY Chen","year":"2021","unstructured":"Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int 2021;41:1265\u20131277.","journal-title":"Liver Int"},{"key":"7483_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/jgh.15192","volume":"36","author":"F Ji","year":"2021","unstructured":"Ji F, Li J, Liu L, Liang J, Wang X, Liu J, Cai D et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. J Gastroenterol Hepatol 2021;36:767\u2013774.","journal-title":"J Gastroenterol Hepatol"},{"key":"7483_CR10","doi-asserted-by":"crossref","unstructured":"Mushtaq S, Mansoor A, Umar M, Khan A, Siddiqi S, Manzoor S. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan. J Med Virol 2020.","DOI":"10.21203\/rs.2.15322\/v1"},{"key":"7483_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MEG.0000000000001283","volume":"31","author":"K Kruger","year":"2019","unstructured":"Kruger K, Krauth C, Rossol S, Mauss S, Boeker KHW, Muller T, Klinker H et al. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. Eur J Gastroenterol Hepatol 2019;31:230\u2013240.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"7483_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/hep.28848","volume":"65","author":"HR Rosen","year":"2017","unstructured":"Rosen HR. \u201cHep C, where art thou\u201d: What are the remaining (fundable) questions in hepatitis C virus research? Hepatology 2017;65:341\u2013349.","journal-title":"Hepatology"},{"key":"7483_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.5694\/mja16.00106","volume":"204","author":"AJ Thompson","year":"2016","unstructured":"Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust 2016;204:268\u2013272.","journal-title":"Med J Aust"},{"key":"7483_CR14","doi-asserted-by":"crossref","unstructured":"Carver AB, Zuckerman AD, DeClercq J, Choi L, Chastain CA. Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy. Open Forum Infect Dis 2020;7:ofaa569.","DOI":"10.1093\/ofid\/ofaa569"},{"key":"7483_CR15","unstructured":"Australian Institute of Health and Welfare (AIHW). Rural, regional and remote health: A guide to remoteness classifications. Canberra, Australia: AIHW; 2004."},{"key":"7483_CR16","unstructured":"Australian Bureau of Statistics (ABS). Census of Population and Housing: Socio-economic Indexes for Areas (SEIFA), Australia, 2006. Canberra, Australia: ABS; 2008."},{"key":"7483_CR17","doi-asserted-by":"crossref","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, M SS, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 2006;43:1317\u20131325.","DOI":"10.1002\/hep.21178"},{"key":"7483_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726\u2013736.","journal-title":"Hepatology"},{"key":"7483_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jhep.2018.04.013","volume":"69","author":"S Bloom","year":"2018","unstructured":"Bloom S, Kemp W, Nicoll A, Roberts SK, Gow P, Dev A, Bell S et al. Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C. J Hepatol 2018;69:575\u2013583.","journal-title":"J Hepatol"},{"key":"7483_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/he.2000.5852","volume":"31","author":"M Malinchoc","year":"2000","unstructured":"Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864\u2013871.","journal-title":"Hepatology"},{"issue":"71","key":"7483_CR21","first-page":"686","volume":"2020","author":"Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance","year":"2019","unstructured":"Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance. Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 2019;2020:686\u2013721.","journal-title":"Hepatology"},{"key":"7483_CR22","doi-asserted-by":"crossref","unstructured":"Stafford F, Dore GJ, Clackett S, Martinello M, Matthews GV, Grebely J, Balcomb AC, et al. Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. Med J Aust 2021.","DOI":"10.5694\/mja2.51204"},{"key":"7483_CR23","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/hep.28782","volume":"64","author":"EB Tapper","year":"2016","unstructured":"Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology 2016;64:1893\u20131899.","journal-title":"Hepatology"},{"key":"7483_CR24","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/jvh.13162","volume":"26","author":"M Lu","year":"2019","unstructured":"Lu M, Wu KH, Li J, Moorman AC, Spradling PR, Teshale EH, Boscarino JA et al. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat 2019;26:1210\u20131217.","journal-title":"J Viral Hepat"},{"key":"7483_CR25","doi-asserted-by":"crossref","unstructured":"Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int 2015;2015:217047.","DOI":"10.1155\/2015\/217047"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07483-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07483-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07483-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T14:44:55Z","timestamp":1700577895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07483-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["7483"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07483-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors do not have any disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all subjects who participated in the study. The Human Ethics Committees of the Royal Brisbane & Women's Hospital (HREC\/15\/QRBW\/183), participating hospitals, and QIMR Berghofer Medical Research Institute (P2126) approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate (ethics)"}}]}}